Get the Stockscreener App
37.12
2.93%
0.9191
Agios Pharmaceuticals Inc stock is traded at $37.12, with a volume of 447.32K.
It is up +2.93% in the last 24 hours and up +31.52% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
See More
Previous Close:
$36.20
Open:
$36.36
24h Volume:
447.32K
Relative Volume:
0.40
Market Cap:
$2.21B
Revenue:
$66.05M
Net Income/Loss:
$-422.60M
P/E Ratio:
-5.1192
EPS:
-7.251
Net Cash Flow:
$-384.73M
1W Performance:
+9.07%
1M Performance:
+31.52%
6M Performance:
+32.98%
1Y Performance:
+10.73%
1-Day Range:
$35.90
$37.42
1-Week Range:
$34.30
$37.42
52-Week Range:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
37.10 | 2.16B | 66.05M | -422.60M | -384.73M | -7.251 |
VRTX
Vertex Pharmaceuticals Inc
|
493.93 | 120.61B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.07 | 65.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.85 | 53.02B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.39 | 39.26B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
179.18 | 36.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Reiterated | H.C. Wainwright | Buy |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
Agios Pharmaceuticals, Inc. Actuals & Estimates (MUN:8AP) - TradingView
AGIO stock surges 35% in six months: What's driving it? - MSN
AGIO Forecast — Price Target — Prediction for 2027 - TradingView
0HB0 Forecast — Price Target — Prediction for 2027 - TradingView
Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026) - AOL.com
Precision Trading with Agios Pharmaceuticals Inc. (AGIO) Risk Zones - Stock Traders Daily
Agios to discontinue candidate for myelodysplastic syndromes - MSN
A Quick Look at Today's Ratings for Agios Pharmaceuticals(AGIO.US), With a Forecast Between $36 to $54 - Moomoo
Agios Pharmaceuticals (AGIO) Is Up 10.3% After New Mitapivat Phase 3 Data and Share Filing – Has The Bull Case Changed? - Sahm
Agios (NASDAQ: AGIO) director exercises RSUs and gains new equity awards - Stock Titan
Agios (NASDAQ: AGIO) director receives new stock options and RSU awards - Stock Titan
Agios Pharmaceuticals (AGIO) director reports new equity awards and RSU vesting - Stock Titan
Agios (NASDAQ: AGIO) director receives new options and RSU awards - Stock Titan
AGIOS (AGIO) director Maykin Ho exercises RSUs and receives new equity awards - Stock Titan
Agios (NASDAQ: AGIO) director receives stock options, RSUs and exercises units - Stock Titan
AGIOS (AGIO) director Scadden exercises RSUs and receives new stock option and RSU awards - Stock Titan
Agios (NASDAQ: AGIO) director reports RSU exercise and new equity grants - Stock Titan
Agios (NASDAQ: AGIO) grants Viswanadhan 6,000 RSU and performance share units - Stock Titan
Agios (NASDAQ: AGIO) CEO Brian Goff receives 39,000 stock-based awards - Stock Titan
[Form 4] AGIOS PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Agios (NASDAQ: AGIO) CMO awarded RSUs, hits milestone for performance units - Stock Titan
AGIOS (NASDAQ: AGIO) CFO receives RSUs and milestone-based performance share units - Stock Titan
Agios Pharmaceuticals Inc (AGIO) Institutional Confidence - TradingKey
Agios Pharmaceuticals (AGIO) Rallies 3.26% as Stock Nears Key Resistance LevelInstitutional Flow Picks - Město Břeclav
Agios Pharma Shareholders Expand Equity Plan, Reelect Directors - TipRanks
Agios Pharmaceuticals (NASDAQ: AGIO) boosts 2023 stock plan by 2M shares - Stock Titan
Agios Targets Transfusion Burden in Sickle Cell Disease With New Phase 3 Bet on Mitapivat - TipRanks
AGIO Stock Surges 35% in Six Months: What's Driving It? - The Globe and Mail
Agios Pharmaceuticals Inc (AGIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Agios Pharmaceuticals Inc (AGIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Agios Pharmaceuticals Inc (AGIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Agios Pharmaceuticals Inc (AGIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Agios Pharmaceuticals Inc (AGIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Agios Pharmaceuticals Inc (AGIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Agios Pharmaceuticals Inc (AGIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Agios Pharmaceuticals Inc (AGIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Agios Pharmaceuticals (AGIO) Stock Could Be 22% Undervalued After RISE UP Phase 3 Data - Sahm
Agios Pharmaceuticals touts mitapivat gains despite sickle cell pain miss - MSN
AGIOS (AGIO) director Catherine Owen Adams converts 1,976 RSUs into common stock - Stock Titan
Agios (NASDAQ: AGIO) director converts 1,976 RSUs, holds 8,049 shares - Stock Titan
Agios Pharmaceuticals (AGIO) Declines as Stock Hovers Between Key Support and Resistance LevelsDealer Positioning - newsline.com
Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor EventSlideshow (NASDAQ:AGIO) 2026-06-15 - Seeking Alpha
Agios Pharmaceuticals (AGIO) Is Up 7.4% After Mitapivat RISE UP Data in Sickle Cell DiseaseHas The Bull Case Changed? - Sahm
Agios Pharmaceuticals (AGIO) Reports Promising Results from Phas - GuruFocus
Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss - Yahoo Finance
AGIO: Mitapivat shows durable efficacy in rare hematology, supporting growth and pipeline expansion - TradingView
Technical Reactions to AGIO Trends in Macro Strategies - Stock Traders Daily
Agios presents detailed mitapivat trial results for sickle cell - Investing.com UK
Agios presents detailed mitapivat trial results for sickle cell By Investing.com - Investing.com Australia
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease - The Manila Times
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):